Press Releases - Cardiol Therapeutics

Investor Resources

Contact Us

Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis

December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

November 14, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis

November 7, 2022

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

October 25, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

October 3, 2022

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

September 28, 2022

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis

August 3, 2022

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

June 29, 2022

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

June 27, 2022